Thrombolytic therapy: current status - summary
Canadian Coordinating Office for Health Technology Assessment
Record ID 31995000010
To identify current controversies and emerging trends about thrombolytic therapy, and examine potential impact in Canada
Authors' results and conclusions: a)The ISIS-3 trial shows no difference in survival between streptokinase, tPA and ASPAC; the debate continues on optimal dosing and administration rates; b) The time between onset of symptoms of AMI and therapy is the most critical factor in achieving significant myocardial salvage and reduced mortality; c) Controversy over patient selection continues; d) There is evidence that adjunctive therapies with anticoagulants or antiplatelets improve efficacy of thrombolytic therapy; e) Approximate costs per treatment are: tPA - $2900, streptokinase - $400, ASPAC - $1900, urokinase - $775. Estimated annual total drug cost in Canada are $77 million (tPA), $51 million (ASPAC) and $12 million (streptokinase).
Authors' recommendations: Future directions include research into earlier administration, noninvasive detection of reperfusion, enhancement of early patency, prevention of reocclusion and reduction of complications.
Authors' methods: Review
Project Status: Completed
URL for project: https://www.ccohta.ca/
Year Published: 1992
English language abstract: An English language summary is available
Publication Type: Not Assigned
- Myocardial Infarction
- Plasminogen Activators
- Tissue Plasminogen Activator
- Urokinase-Type Plasminogen Activator
- Fibrinolytic Agents
Organisation Name: Canadian Coordinating Office for Health Technology Assessment
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name: email@example.com
Contact Email: firstname.lastname@example.org
Copyright: Canadian Coordinating Office for Health Technology Assessment.
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.